Barclays Maintains Overweight on AbbVie, Raises Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on AbbVie (NYSE:ABBV) and raises the price target from $187 to $200.
July 26, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on AbbVie and raises the price target from $187 to $200, indicating confidence in the company's future performance.
The raised price target and maintained Overweight rating from a reputable analyst at Barclays suggest a positive outlook for AbbVie's stock. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100